SecBot SecBot
PRESS-RELEASE ·Filed Jul 23, 2026

WST

West Pharmaceutical Services, Inc.
BULLISH
Impact 7/10
Horizondays Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The beat-and-raise quarter with strong HVP and biologics growth confirms accelerating demand for West's high-value injectable components. Traders should watch for continued margin expansion and any updates on the SmartDose sale to AbbVie. The raised guidance provides a clear upward catalyst for the stock in the near term.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$355.48
T+0 close · Jul 23, 2026 · via day close
Latest settled
+7.75%
T+60 · $383.02
Vs SPY
+3.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 23 $355.48entry
  2. T+1 · 4mo ago −7.67%α −7.78% · $328.20
  3. T+5 · 4mo ago −4.47%α −4.95% · $339.59
  4. T+20 · 3mo ago −0.48%α −3.79% · $353.77
  5. T+60 · 5w ago +7.75%α +3.19% · $383.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

West Pharmaceutical reported Q2 2026 net sales of $872.3M (+13.8% YoY) and diluted EPS of $2.15 (+18.1% YoY), beating consensus estimates of $840M and $2.08. The company raised full-year 2026 adjusted-diluted EPS guidance to $8.85-$9.05 (from $8.40-$8.75) and net sales guidance to $3.345B-$3.380B, driven by strong HVP Components (+19.4%) and Biologics (+30.3%) growth. The beat and raised guidance signal accelerating demand for injectable solutions, particularly in GLP-1 and biologics, making this a clear positive catalyst for the stock.

Key Financial Metrics

EPS
$2.15
est $2.08 · +3.4%
Revenue
$872.3M
est $840.0M · +3.9% · +13.8% YoY
Rating
beat
Guidance
$3.345B-$3.380B
raised
Free Cash Flow
$128.0M
Gross Margin
37.7%

Key Facts

  • Q2 2026 net sales of $872.3M beat $840M consensus (+3.8% surprise)
  • Diluted EPS of $2.15 beat $2.08 consensus (+3.4% surprise)
  • Adjusted-diluted EPS of $2.37 increased 28.8% YoY
  • Full-year 2026 adjusted-diluted EPS guidance raised to $8.85-$9.05 from $8.40-$8.75
  • Full-year 2026 net sales guidance raised to $3.345B-$3.380B from $3.295B-$3.350B
  • HVP Components net sales grew 19.4% to $424.1M, 49% of total sales
  • Biologics market group net sales grew 30.3% to $374.8M
  • Operating cash flow was $213.9M; free cash flow was $128.0M
  • Company repurchased 1.8M shares for $454.3M in H1 2026

Financial Impact

Beat consensus by $32.3M on revenue and $0.07 on EPS; raised full-year EPS guidance by $0.45 at midpoint

revenueepsguidanceoperating cash flow

Risk Factors

  • SmartDose 3.5mL sale to AbbVie creates a $55M revenue headwind in H2 2026
  • Foreign exchange headwinds of ~1% on full-year guidance
  • Cost-method investment impairment of $3.5M in Q2

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302832704

Track record

17 reports on WST

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $392.48 Now $417.80 +6.45% settles Feb 3
  2. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  3. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $416.67 Now $417.80 +0.27% settles Jan 27
  4. Oct 26, 202621d ago 8-K Neutral 4/10 Entry $398.29 Now $417.80 +4.90% settles Jan 25
  5. Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $394.73 Now $417.80 +5.84% settles Jan 22
  6. Jul 23, 202616w ago 8-K Bullish 7/10 No price data
  7. Jul 23, 202616w ago Press Release Bullish 7/10 Viewing Entry $355.48 to $383.02 Now $417.80 +17.53% ▲ +7.75% +3.19% vs SPY
  8. Jul 7, 202618w ago Press Release Neutral 1/10 Entry $356.08 to $370.76 Now $417.80 +17.33% ▲ +4.12% +2.13% vs SPY
  9. May 11, 202627w ago 8-K Bearish 7/10 Entry $311.82 to $348.06 Now $417.80 −33.99% ▼ −11.62% −7.51% vs SPY
  10. Apr 27, 202629w ago Insider Cluster Neutral 2/10 Entry $300.93 to $358.41 Now $417.80 +38.83% ▲ +19.10% +14.59% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 23, 2026